A phase I, open-label, dose-escalation trial to evaluate the safety and tolerability of the combination of orally received pazopanib once every other day with continuous daily dosing of lapatinib in patients with solid tumours
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Pazopanib (Primary) ; Lapatinib
- Indications Bladder cancer; Head and neck cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
- Focus Therapeutic Use
- 02 Feb 2016 New trial record